subdued response, page-20

No rush. Steady wins the race. The pipeline is really coming along nicely. Still some risks ahead but with some luck success will be reflected in value. A US manufacturing facility needs to be set up pronto if they are considering phase II next winter. Inavir sales will be very interesting indeed. RSV and other pipeline drugs could surprise. Market is pretty funny but I ain't selling anywhere near these levels.